Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivita in Amyotrophic Lateral Sclerosis
NCT03103815Unknown
- Sponsor
- Changzhou Wujin People's Hospital
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-blind trial of Amivita in amyotrophic lateral sclerosis (ALS), sponsored by Changzhou Wujin People's Hospital. Primary endpoints: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 10 months, Adverse events at 10 months and 1 more. Status: unknown.
02
Drugs
Amivita
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03103815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103815.